Platforms for production of protein-based vaccines: from classical to next-generation strategies
R Cid, J Bolívar - Biomolecules, 2021 - mdpi.com
R Cid, J Bolívar
Biomolecules, 2021•mdpi.comTo date, vaccination has become one of the most effective strategies to control and reduce
infectious diseases, preventing millions of deaths worldwide. The earliest vaccines were
developed as live-attenuated or inactivated pathogens, and, although they still represent the
most extended human vaccine types, they also face some issues, such as the potential to
revert to a pathogenic form of live-attenuated formulations or the weaker immune response
associated with inactivated vaccines. Advances in genetic engineering have enabled …
infectious diseases, preventing millions of deaths worldwide. The earliest vaccines were
developed as live-attenuated or inactivated pathogens, and, although they still represent the
most extended human vaccine types, they also face some issues, such as the potential to
revert to a pathogenic form of live-attenuated formulations or the weaker immune response
associated with inactivated vaccines. Advances in genetic engineering have enabled …
To date, vaccination has become one of the most effective strategies to control and reduce infectious diseases, preventing millions of deaths worldwide. The earliest vaccines were developed as live-attenuated or inactivated pathogens, and, although they still represent the most extended human vaccine types, they also face some issues, such as the potential to revert to a pathogenic form of live-attenuated formulations or the weaker immune response associated with inactivated vaccines. Advances in genetic engineering have enabled improvements in vaccine design and strategies, such as recombinant subunit vaccines, have emerged, expanding the number of diseases that can be prevented. Moreover, antigen display systems such as VLPs or those designed by nanotechnology have improved the efficacy of subunit vaccines. Platforms for the production of recombinant vaccines have also evolved from the first hosts, Escherichia coli and Saccharomyces cerevisiae, to insect or mammalian cells. Traditional bacterial and yeast systems have been improved by engineering and new systems based on plants or insect larvae have emerged as alternative, low-cost platforms. Vaccine development is still time-consuming and costly, and alternative systems that can offer cost-effective and faster processes are demanding to address infectious diseases that still do not have a treatment and to face possible future pandemics.
![](/scholar/images/qa_favicons/mdpi.com.png)
以上显示的是最相近的搜索结果。 查看全部搜索结果